John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

AbbVie says that navitoclax is a first-in-class therapy, targeting a different part of the BCL-2 pathway to Roche-partnered Venclexta (venetoclax), which is approved to treat chronic lymphocytic ...

BAD is a pro-apoptotic member of the Bcl-2 family that is tightly regulated by survival factors. Several major signalling pathways influence cell death through their direct effects on the ...

Identification of six cancer susceptibility genes offers new insights into genetic risk factors, potentially enhancing early ...

Selective modulation of the apoptotic machinery has been the goal of oncology developers for more than two decades. The field continues to face special challenges. Many of the targets are ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

Bcl-2 levels decreased with SLE sera exposure and ... protein levels and AMPK activity to normal levels). The SIRT3-AMPK pathway is crucial in inhibiting endothelial dysfunction by limiting ...

Pathways students need to complete 16 graded credit hours of non-remedial coursework with a minimum 2.00 GPA before gaining full admission to the Oxford campus. Do AP credits count toward the 16 hours ...

ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML treatment ... suggest enhanced activation of stress signaling pathways. These molecular readouts were ...

although alternative methods of targeting these pathways may be effective. MEK inhibitors form the backbone of multiple regimens entering clinical trials and are being combined with BCL-XL ...

Developed by Ascentage Pharma, lisaftoclax is a novel orally available Bcl-2 inhibitor with clinical benefits for an array of hematologic malignancies and solid tumors. At this year's ASH Annual ...